A synthetic-biology collagen leader derated to value levels, betting its next leg of growth on Class III injectable aesthetics.
Overview
Giant Biogene (2367.HK) is a leading biotech-beauty company and early pioneer of recombinant collagen industrialization, positioned at the intersection of synthetic biology, professional skincare, and medical aesthetics. Founded in 2000 from Northwest University labs, it has evolved into a vertically integrated developer/manufacturer of bioactive ingredient-based professional skin treatments, medical devices, and functional health foods. Its core edge is a proprietary synthetic biology platform producing recombinant collagen that matches human collagen sequences, improving safety/consistency versus animal collagen and creating a high-barrier moat in clinical skincare and aesthetics. Revenue is diversified across functional skincare (the main engine, led by Comfy/Kefumei and Collgene/Kelijin), medical dressings/devices (Class II/III), and an emerging injectable filler pipeline. Financially, FY2024 was a breakout year (revenue RMB 5.54B, +57.2% YoY; net profit RMB 2.06B) with sustained best-in-class margins (gross >80%, net ~37–38%). H1 2025 showed deliberate/forced deceleration (revenue +22.5%) amid tougher comps, a May 2025 public-opinion incident related to ingredients, and rising competition in China’s cosmetics market—yet profitability remained exceptional. Distribution is extensive (hospitals/clinics/pharmacies/retail) and increasingly digital, with online contributing 71.6% of 2024 revenue, creating a powerful loop where medical endorsement builds trust and e-commerce scales volume. With landmark approvals of recombinant collagen facial injectables in late 2025 and early 2026, the company is positioned to enter a new phase targeting the high-margin injectable aesthetics market, which could become a second growth engine if adoption and brand trust hold.